^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CFI-402411
i
Other names: CFI-402411, CFI402411, CFI 402411
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Treadwell Therap
Drug class:
HPK1 inhibitor
Related drugs:
8ms
TWT-101: Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies (clinicaltrials.gov)
P1/2, N=170, Recruiting, Treadwell Therapeutics, Inc | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Nov 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • CFI-402411
almost3years
TWT-101: Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies (clinicaltrials.gov)
P1/2, N=170, Recruiting, Treadwell Therapeutics, Inc | Trial primary completion date: Dec 2021 --> Dec 2023
Trial primary completion date • Combination therapy
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • CFI-402411
4years
Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies (clinicaltrials.gov)
P1/2, N=170, Recruiting, Treadwell Therapeutics, Inc | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy • PD(L)-1 Biomarker
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • CFI-402411
over4years
Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies (clinicaltrials.gov)
P1/2, N=170, Not yet recruiting, Treadwell Therapeutics, Inc
Clinical • New P1/2 trial • Combination therapy • PD(L)-1 Biomarker
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • CFI-402411
Share via
